Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma

NCT02587650 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02587650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02587650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Terminated
Start date
March 26, 2015
Completion date
July 12, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk fusion protein expression, braf wt allele, invasive skin melanoma, met fusion gene positive, nras wt allele, ntrk1 fusion positive, ntrk2 fusion positive, ntrk3 fusion positive, ret fusion positive, ros1 fusion positive, stage iii cutaneous melanoma, stage iiia cutaneous melanoma, stage iiib cutaneous melanoma, stage iiic cutaneous melanoma, stage iv cutaneous melanoma